8-K: LAVA Therapeutics Tender Offer Extended by XOMA Royalty

XOMA Royalty Corporation has extended its tender offer to acquire all outstanding common shares of LAVA Therapeutics N.V. until October 17, 2025.

Summary

• XOMA Royalty Corporation extended its tender offer to acquire all issued and outstanding common shares of LAVA Therapeutics N.V.
• The tender offer, previously scheduled to expire on October 3, 2025, has been extended to October 17, 2025.
• The consideration for each share includes a cash amount (to be determined) plus a non-transferable contingent value right (CVR).
• The CVR entitles shareholders to receive 75% of the net proceeds from LAVA's two partnered assets and 75% of any net proceeds from out-licensing or sale of unpartnered programs.
• LAVA shareholders who have already tendered their shares do not need to take any further action.
• The closing of the offer is subject to conditions, including the tender of at least 80% (or 75% in certain cases) of LAVA's outstanding shares, adoption of certain shareholder resolutions, and a minimum cash balance at closing.
• A corporate reorganization is planned after a subsequent offering period, aiming for XOMA Royalty to acquire 100% of LAVA's successor.
• LAVA will hold a shareholders meeting in connection with the transactions prior to early November 2025.

Sentiment

Score: 4

Explanation: The extension of a tender offer, while not necessarily a deal-breaker, introduces uncertainty and suggests that initial conditions were not met as planned. This can be viewed negatively by the market, even if shareholder support is noted. The CVR offers potential upside but is non-transferable and contingent, adding a layer of risk.

Positives

• LAVA shareholders have signed support agreements to tender their shares, indicating strong backing for the acquisition.
• The extension provides additional time for shareholders to tender their shares, potentially facilitating the satisfaction of the minimum tender condition.

Negatives

• The extension of the tender offer suggests that the initial conditions for closing might not have been met or required more time, potentially signaling a slower-than-expected process.
• Transaction-related uncertainty could disrupt LAVA's business and relationships with employees, manufacturers, suppliers, vendors, or business partners.
• Significant costs are associated with the transactions.
• There is a risk that activities related to the CVR agreement may not result in any value to LAVA's shareholders.

Risks

• The possibility that various closing conditions, including the minimum tender percentage, shareholder resolutions, and minimum cash balance, may not be satisfied or waived.
• Uncertainties regarding the percentage of LAVA's shareholders tendering their shares in the offer.
• The possibility that competing offers for LAVA Therapeutics may emerge.
• The risk that the transactions may not be completed in a timely manner, or at all, which could adversely affect LAVA's business and the price of its ordinary shares.
• The delay or failure of the Offer Conditions to be satisfied (or waived), including insufficient common shares of LAVA being tendered.
• Significant costs associated with the Transactions.
• The risk that any shareholder or other litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• The risk that activities related to the CVR agreement may not result in any value to LAVA's shareholders.
• The possibility that prior to the completion of the transactions, LAVA's or XOMA Royalty's business may experience significant disruptions due to transaction-related uncertainty.
• The effects of disruption from the transactions on LAVA's business, potentially making it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Purchase Agreement.
• Potential adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities (e.g., Russian invasion of Ukraine, Middle East conflict).

Future Outlook

The proposed acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions. Following a subsequent offering period, LAVA will undergo a corporate reorganization designed to result in XOMA Royalty acquiring 100% of the shares in LAVA's successor.

Industry Context

This transaction represents a strategic acquisition in the biotechnology sector, where royalty aggregators like XOMA Royalty acquire biopharmaceutical companies with promising pipelines. LAVA Therapeutics, with its Gammabody platform and partnered assets, fits the profile of a company whose assets could be monetized. The extension of the tender offer is not uncommon in complex M&A deals, especially in biotech where regulatory approvals or shareholder participation thresholds can be challenging, reflecting the inherent complexities and due diligence required in such transactions.

Stakeholder Impact

• Shareholders: Will receive cash and a non-transferable CVR for their shares; urged to read revised proxy statement and tender offer materials before making decisions. Face the risk that the CVR may not result in any value.
• Employees: Potential for significant disruptions to relationships due to transaction-related uncertainty.
• Manufacturers, Suppliers, Vendors, Business Partners: Potential for significant disruptions to relationships due to transaction-related uncertainty.

Next Steps

• XOMA Royalty will file an amendment to its Tender Offer Statement on Schedule TO with the SEC.
• LAVA will file an updated Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• LAVA plans to send a revised proxy statement and proxy card to each shareholder entitled to vote at the reconvened extraordinary general meeting.
• LAVA will hold a shareholders meeting in connection with the transactions prior to early November 2025.
• The proposed acquisition is expected to close in the fourth quarter of 2025.
• Following a subsequent offering period, LAVA will undergo a corporate reorganization.

Key Dates

Recommendation

The extension of the tender offer introduces a degree of uncertainty, suggesting that the initial conditions for the acquisition were not met as smoothly as anticipated. While shareholder support agreements are positive, the delay and the contingent nature of a significant portion of the consideration (CVR) warrant caution. Investors should hold their shares and await further developments, particularly the outcome of the extended tender offer and the details of the cash component, before making further decisions. The CVR's value is speculative and depends on future monetization events, adding a layer of risk that needs careful consideration.

Keywords

LAVA Therapeutics, XOMA Royalty, Tender Offer, Acquisition, Biotech, Biopharmaceutical, Contingent Value Right, CVR, M&A, NASDAQ, LVTX, XOMA, Gammabody